Manajement

First And Only FDA-Approved Type Ii Raf Inhibitor For Patients With Relapsed Or Refractory Plgg Harboring A Braf Fusion Or Rearrangement, Or Braf V600 Mutation Made Possible Through PNOC Clinical Trial FOLLOWING SUCCESSFUL FIREFLY-1 TRIAL IN PARTNERSHIP WITH THE PNOC SCIENTIFIC CONSORTIUM…

  

By

Leave a Reply

Your email address will not be published. Required fields are marked *